Daily Stock Opinions and Ratings

Opinions

Jim Cramer - Mad MoneyRegeneron Pharmaceuticals IncREGNBUYJun 14, 2024

He's bullish pharmas if the economy weakens. He likes it for growing organically, not buying companies, and in developing its drugs in-house or with partners. Their drug pipeline overcomes worries of their existing drugs coming off patent. Their key drug, Eylea, topped $1.04 billion in Q1 and $5.89 billion in full-year US net sales. But Roche has released a rival drug, while Eylea will come off patent in a couple years as they successfully protect their patent in court. Also, REGN just developed a new version of Eylea. Dupixent is their second-biggest drug and is performing well as well. Despite its growth, REGN trades at only 22x forward PE, and announced a $3 billion share buyback.

Jim Cramer - Mad Money

Unknown

Unlock Rating

$1037.31

Stock price when the opinion was issued

$609.94

As of Jun 18, 2026. Market Open.

Pharma & Healthcare

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

DON'T BUY

It got blasted on a cancer drug trial's results. He expected it to succeed. It fell 10% today. Could be more downgrades to come.

COMMENT

Up 53% the last 6 months. He lost sight of this and shouldn't have. His bad.

BUY ON WEAKNESS

It's lost a third of its market cap and the selling is overdone. Now, is a buying opportunity.

BUY

Run by a fine CEO. Shares are up long term, and they have a lot of promising drugs in their pipeline, including one in weight-loss.

BUY

It's had bad news this week, but it rarely gets a pull back. Long term this is fine.

WATCH

Are showcasing their key drugs next week, but he remains focused on their obesity drug candidate. It's still early in those test results.

BUY

An analyst upgraded this to $1,025, a very long way to go. He's gained 40% in this himself. It's reasonable at a 24x PE and enjoys momentum. Sees nothing to derail this.

DON'T BUY

The momentum is waning, and last quarter revenue growth was only 14%. They're coming to the end of the road.

BUY

Shares are down in the past 24 hours due to a delay in a drug approval. But another drug remains strong in sales, and they have double-digit in oncology drugs in trials. A great science company.

WEAK BUY

A quality company. Trades at 17x. The FDA is delaying approval of a drug, but that is correctable because the issue isn't about safety or efficacy.

BUY

Trades at 19x earnings, but have a huge drug pipeline.

BUY

Was upgraded today. He regrets not owning it. Great managers. Owning a biotech ETF like XBI is fine for risk management. Healthcare is recession-resistant and he loves it.

HOLD

She wishes that today's upgrade had come earlier. 2023 earnings will be flat, not great, but they have some new drugs will drive earnings in the future. This stock could do nothing for a while, but nothing wrong to hold it; earnings may stay flat.

STRONG BUY

His favourite stock in his favourite sector. It is up 18% YTD.

Most Recent Experts

Chris Blumas

at Raymond James Investment Counsel Ltd.

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase